Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; State Petitions for Exemption From Preemption, 63128-63129 [2014-25106]
Download as PDF
63128
Federal Register / Vol. 79, No. 204 / Wednesday, October 22, 2014 / Notices
The reporting and third-party
disclosure burden estimates are based
on our records, which show that there
are 5 manufacturers of infant formula
and that there have been, on average, 2
infant formula recalls per year for the
past 3 years. Based on this information,
we estimate that there will be, on
average, approximately 2 infant formula
recalls per year over the next 3 years.
Thus, we estimate that 2 respondents
will conduct recalls annually pursuant
to §§ 107.230, 107.240, and 107.250.
The estimated number of respondents
for § 107.260 is minimal because we
seldom use this section; therefore, we
estimate that there will be 1 or fewer
respondents annually for § 107.260. The
estimated number of hours per response
is an average based on our experience
and information from firms that have
conducted recalls. We estimate that 2
respondents will conduct infant formula
recalls under § 107.230 and that it will
take a respondent 4,450 hours to comply
with the requirements of that section,
for a total of 8,900 hours. We estimate
that 2 respondents will conduct infant
formula recalls under § 107.240 and that
it will take a respondent 1,482 hours to
comply with the requirements of that
section, for a total of 2,964 hours. We
estimate that 2 respondents will submit
recommendations for termination of
infant formula recalls under § 107.250
and that it will take a respondent 120
hours to comply with the requirements
of that section, for a total of 240 hours.
Finally, we estimate that 1 respondent
will need to carry out additional
effectiveness checks and issue
additional notifications, for a total of
625 hours.
Under 5 CFR 1320.3(b)(2), the time,
effort, and financial resources necessary
to comply with a collection of
information are excluded from the
burden estimate if the reporting,
recordkeeping, or disclosure activities
needed to comply are usual and
customary because they would occur in
the normal course of activities. No
burden has been estimated for the
recordkeeping requirement in § 107.280
because these records are maintained as
a usual and customary part of normal
business activities. Manufacturers keep
infant formula distribution records for
the prescribed period as a matter of
routine business practice.
TABLE 2—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN 1
Number of
disclosures per
respondent
Number of
respondents
21 CFR section; activity
Total annual
disclosures
Average burden
per disclosure
Total hours
107.230; elements of infant formula recall ......
107.260; revision of an infant formula recall ...
2
1
1
1
2
1
50
25
100
25
Total ..........................................................
............................
............................
............................
............................
125
mstockstill on DSK4VPTVN1PROD with NOTICES
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Table 2 reports our third-party
disclosure burden estimates for
§§ 107.230 and 107.260. The estimated
burden hours per disclosure is an
average based on our experience. The
third-party disclosure burden in
§ 107.230 is the requirement to
promptly notify each affected directaccount (customer) about the recall, and
if the recalled formula presents a risk to
human health, the requirement that the
recalling firm must also request that
each establishment that sells the
recalled formula post a notice of the
recall at the point of purchase. We
estimate that 2 respondents will
conduct infant formula recalls under
§ 107.230 and that it will take a
respondent 50 hours to comply with the
third-party disclosure requirements of
that section, for a total of 100 hours. The
third-party disclosure burden in
§ 107.260 is the requirement to issue
additional notifications where the recall
strategy or implementation is
determined to be deficient. We estimate
that 1 respondent will issue additional
notifications under § 107.260 and that it
will take a respondent 25 hours to
comply with the third-party disclosure
requirements of that section, for a total
of 25 hours.
VerDate Sep<11>2014
18:22 Oct 21, 2014
Jkt 235001
Dated: October 16, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–25105 Filed 10–21–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–1104]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; State Petitions for
Exemption From Preemption
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by November
21, 2014.
ADDRESSES: To ensure that comments on
the information collection are received,
SUMMARY:
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0277. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd.; COLE–14526, Silver
Spring, MD 20993–0002 PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
State Petitions for Exemption From
Preemption—21 CFR 100.1(d) (OMB
Control Number 0910–0277)—
(Extension)
Under section 403A(b) of the Federal
Food, Drug, and Cosmetic Act (the
FD&C Act) (21 U.S.C. 343–1(b)), states
may petition FDA for exemption from
Federal preemption of state food
labeling and standard of identity
requirements. Section 100.1(d) (21 CFR
100.1(d)) sets forth the information a
E:\FR\FM\22OCN1.SGM
22OCN1
Federal Register / Vol. 79, No. 204 / Wednesday, October 22, 2014 / Notices
comment on the proposed collection of
information. No comments were
received.
We estimate the annual burden of this
collection of information as follows:
section 403A(b) of the FD&C Act for
granting exemption from Federal
preemption.
In the Federal Register of August 7,
2014 (79 FR 46269), FDA published a
60-day notice requesting public
state is required to submit in such a
petition. The information required
under § 100.1(d) enables FDA to
determine whether the state food
labeling or standard of identity
requirement satisfies the criteria of
63129
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
21 CFR 100.1(d)
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Avg. burden per
response
Total hours
Form of petition ................................................
1
1
1
40
40
1
There are no capital costs or operating and maintenance costs associated with this collection of information.
The reporting burden for § 100.1(d) is
minimal because petitions for
exemption from preemption are seldom
submitted by states. In the last 3 years,
we have received one new petition for
exemption from preemption; therefore,
we estimate that one or fewer petitions
will be submitted annually.
Dated: October 16, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–25106 Filed 10–21–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–D–1540]
Migraine: Developing Drugs for Acute
Treatment; Draft Guidance for
Industry; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance for
industry entitled ‘‘Migraine: Developing
Drugs for Acute Treatment.’’ The
purpose of this guidance is to assist
sponsors in the clinical development of
drugs for the acute treatment of
migraine. This guidance focuses on
specific drug development and trial
design issues that are unique to the
study of drugs for the acute treatment of
migraine. This guidance is intended to
serve as a focus for continued
discussions among the Division of
Neurology Products, pharmaceutical
sponsors, the academic community, and
the public.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency
considers your comment on this draft
guidance before it begins work on the
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:22 Oct 21, 2014
Jkt 235001
final version of the guidance, submit
either electronic or written comments
on the draft guidance by December 22,
2014.
ADDRESSES: Submit written requests for
single copies of the draft guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993.
Send one self-addressed adhesive label
to assist that office in processing your
requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the draft guidance document.
Submit electronic comments on the
draft guidance to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Eric
Bastings, Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 22, Rm. 4338, Silver Spring,
MD 20993–0002, 301–796–1039.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance for industry entitled
‘‘Migraine: Developing Drugs for Acute
Treatment.’’ The purpose of this
guidance is to assist sponsors in the
clinical development of drugs for the
acute treatment of migraine. This
guidance focuses on specific drug
development and trial design issues that
are unique to the study of drugs for the
acute treatment of migraine. This
guidance is intended to serve as a focus
for continued discussions among the
Division of Neurology Products,
pharmaceutical sponsors, the academic
community, and the public.
Migraine is a chronic neurovascular
disorder characterized by recurrent
attacks of often severe headache,
typically presenting with nausea,
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
vomiting, and sensitivity to light and/or
sound. Pharmacologic approaches to the
treatment of migraine include drugs to
treat acute migraine attacks as they arise
(acute treatment of migraine) and drugs
to reduce the frequency of migraine
attacks (preventive treatment). This
guidance addresses the development
program of drugs for the acute treatment
of migraine, including trial population,
trial design, dose selection, efficacy
endpoints, and statistical
considerations. The guidance also
discusses safety considerations,
pediatric studies, and labeling
considerations.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the Agency’s current thinking
on developing drugs for the acute
treatment of migraine. It does not create
or confer any rights for or on any person
and does not operate to bind FDA or the
public. An alternative approach may be
used if such approach satisfies the
requirements of the applicable statutes
and regulations.
II. The Paperwork Reduction Act of
1995
This guidance refers to previously
approved collections of information that
are subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3520). The collections
of information in 21 CFR parts 201, 312,
and 314 have been approved under
OMB control numbers 0910–0572,
0910–0014, and 0910–0001,
respectively.
III. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
E:\FR\FM\22OCN1.SGM
22OCN1
Agencies
[Federal Register Volume 79, Number 204 (Wednesday, October 22, 2014)]
[Notices]
[Pages 63128-63129]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-25106]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-1104]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; State Petitions for
Exemption From Preemption
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by
November 21, 2014.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0277.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 8455 Colesville Rd.; COLE-14526, Silver
Spring, MD 20993-0002 PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
State Petitions for Exemption From Preemption--21 CFR 100.1(d) (OMB
Control Number 0910-0277)--(Extension)
Under section 403A(b) of the Federal Food, Drug, and Cosmetic Act
(the FD&C Act) (21 U.S.C. 343-1(b)), states may petition FDA for
exemption from Federal preemption of state food labeling and standard
of identity requirements. Section 100.1(d) (21 CFR 100.1(d)) sets forth
the information a
[[Page 63129]]
state is required to submit in such a petition. The information
required under Sec. 100.1(d) enables FDA to determine whether the
state food labeling or standard of identity requirement satisfies the
criteria of section 403A(b) of the FD&C Act for granting exemption from
Federal preemption.
In the Federal Register of August 7, 2014 (79 FR 46269), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
We estimate the annual burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
21 CFR 100.1(d) Number of responses per Total annual Avg. burden per Total hours
respondents respondent responses response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Form of petition......................................... 1 1 1 40 40
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
The reporting burden for Sec. 100.1(d) is minimal because
petitions for exemption from preemption are seldom submitted by states.
In the last 3 years, we have received one new petition for exemption
from preemption; therefore, we estimate that one or fewer petitions
will be submitted annually.
Dated: October 16, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-25106 Filed 10-21-14; 8:45 am]
BILLING CODE 4164-01-P